AYTU has been successfully added to your Stock Email Alerts list.
You can manage your stock email alerts here.
AYTU has been removed from your Stock Email Alerts list.
Please enter Portfolio Name for new portfolio.
As of today (2024-04-29), Aytu BioPharma's current share price is $2.9043. Aytu BioPharma's Cyclically Adjusted Revenue per Share for the quarter that ended in Dec. 2023 was $2,611.27. Aytu BioPharma's Cyclically Adjusted PS Ratio for today is 0.00.
The historical rank and industry rank for Aytu BioPharma's Cyclically Adjusted PS Ratio or its related term are showing as below:
During the past years, Aytu BioPharma's highest Cyclically Adjusted PS Ratio was 2.82. The lowest was 0.01. And the median was 0.05.
The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted revenue per share of a company over the past 10 years.
Aytu BioPharma's adjusted revenue per share data for the three months ended in Dec. 2023 was $4.156. Add all the adjusted revenue per share for the past 10 years together and divide 10 will get our Cyclically Adjusted Revenue per Share, which is $2,611.27 for the trailing ten years ended in Dec. 2023.
The historical data trend for Aytu BioPharma's Cyclically Adjusted PS Ratio can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Aytu BioPharma Quarterly Data | ||||||||||||||||||||
Mar19 | Jun19 | Sep19 | Dec19 | Mar20 | Jun20 | Sep20 | Dec20 | Mar21 | Jun21 | Sep21 | Dec21 | Mar22 | Jun22 | Sep22 | Dec22 | Mar23 | Jun23 | Sep23 | Dec23 | |
Cyclically Adjusted PS Ratio | Get a 7-Day Free Trial | - | - | - | - | - |
For the Drug Manufacturers - Specialty & Generic subindustry, Aytu BioPharma's Cyclically Adjusted PS Ratio, along with its competitors' market caps and Cyclically Adjusted PS Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
For the Drug Manufacturers industry and Healthcare sector, Aytu BioPharma's Cyclically Adjusted PS Ratio distribution charts can be found below:
* The bar in red indicates where Aytu BioPharma's Cyclically Adjusted PS Ratio falls into.
Like the Shiller PE Ratio, the Cyclically Adjusted PS Ratio takes the Revenue per Share from the past 10 years, adjusts it for inflation, and then calculates the average. This average is then used for the P/S calculation. Because it considers this 10-year average, it's often referred to as the CAPS Ratio.
The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PS Ratio.
Aytu BioPharma's Cyclically Adjusted PS Ratio for today is calculated as
Cyclically Adjusted PS Ratio | = | Share Price | / | Cyclically Adjusted Revenue per Share |
= | 2.9043 | / | 2611.27 | |
= | 0.00 |
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Aytu BioPharma's Cyclically Adjusted Revenue per Share for the quarter that ended in Dec. 2023 is calculated as:
For example, Aytu BioPharma's adjusted Revenue per Share data for the three months ended in Dec. 2023 was:
Adj_RevenuePerShare | = | Revenue per Share | / | CPI of Dec. 2023 (Change) | * | Current CPI (Dec. 2023) |
= | 4.156 | / | 129.4194 | * | 129.4194 | |
= | 4.156 |
Current CPI (Dec. 2023) = 129.4194.
Aytu BioPharma Quarterly Data
Revenue per Share | CPI | Adj_RevenuePerShare | |
201402 | 0.000 | 99.057 | 0.000 |
201405 | 0.000 | 100.373 | 0.000 |
201408 | 0.000 | 100.352 | 0.000 |
201411 | 0.000 | 99.635 | 0.000 |
201502 | 0.000 | 99.032 | 0.000 |
201506 | 0.000 | 100.684 | 0.000 |
201509 | 0.000 | 100.392 | 0.000 |
201512 | 0.000 | 99.792 | 0.000 |
201603 | 0.000 | 100.470 | 0.000 |
201606 | 0.000 | 101.688 | 0.000 |
201609 | 0.000 | 101.861 | 0.000 |
201612 | 0.000 | 101.863 | 0.000 |
201703 | 6,385.714 | 102.862 | 8,034.392 |
201706 | 4,917.647 | 103.349 | 6,158.147 |
201709 | 1,076.000 | 104.136 | 1,337.249 |
201712 | 1,051.000 | 104.011 | 1,307.743 |
201803 | 202.333 | 105.290 | 248.703 |
201806 | 102.778 | 106.317 | 125.112 |
201809 | 159.111 | 106.507 | 193.340 |
201812 | 56.094 | 105.998 | 68.489 |
201903 | 52.844 | 107.251 | 63.767 |
201906 | 19.500 | 108.070 | 23.352 |
201909 | 18.701 | 108.329 | 22.342 |
201912 | 36.080 | 108.420 | 43.068 |
202003 | 46.341 | 108.902 | 55.072 |
202006 | 23.626 | 108.767 | 28.112 |
202009 | 22.237 | 109.815 | 26.207 |
202012 | 22.812 | 109.897 | 26.864 |
202103 | 14.898 | 111.754 | 17.253 |
202106 | 19.968 | 114.631 | 22.544 |
202109 | 342.141 | 115.734 | 382.598 |
202112 | 17.506 | 117.630 | 19.261 |
202203 | 16.307 | 121.301 | 17.398 |
202206 | 15.266 | 125.017 | 15.804 |
202209 | 10.983 | 125.227 | 11.351 |
202212 | 8.450 | 125.222 | 8.733 |
202303 | 6.100 | 127.348 | 6.199 |
202306 | 7.566 | 128.729 | 7.607 |
202309 | 4.031 | 129.860 | 4.017 |
202312 | 4.156 | 129.419 | 4.156 |
Add all the adjusted revenue per share together and divide 10 will get our Cyclically Adjusted Revenue per Share.
Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.
Compared with the regular PS Ratio, which works poorly for cyclical businesses, the Cyclically Adjusted PS Ratio smoothed out the fluctuations of revenue during business cycles. Therefore it is more accurate in reflecting the valuation of the company.
If a company has consistent business performance, the Cyclically Adjusted PS Ratio should give similar results to regular PS Ratio.
Thank you for viewing the detailed overview of Aytu BioPharma's Cyclically Adjusted PS Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.
Christopher Brooke | officer: Chief Operating Officer | C/O AYTU BIOPHARMA, INC., 373 INVERNESS PARKWAY, SUITE 206, ENGLEWOOD CO 80112 |
Jarrett Disbrow | officer: Chief Business Officer | 373 INVERNESS PARKWAY, SUITE 200, ENGLEWOOD CO 80112 |
John Jr. Donofrio | director | C/O AYTU BIOSCIENCE, INC., 373 INVERNESS PARKWAY, SUITE 200, ENGLEWOOD CO 80112 |
Carl Dockery | director | P.O. BOX 2477, LAKELAND FL 33806-2477 |
Vivian H Liu | director | |
Mark K Oki | officer: Chief Financial Officer | C/O ALEXZA PHARMACEUTICALS INC, 2091 STIERLIN COURT, MOUNTAIN VIEW CA 94043 |
Joshua R. Disbrow | director, officer: Chief Executive Officer | AMPIO PHARMACEUTICALS, INC., 5445 DTC PARKWAY, SUITE 925, GREENWOOD VILLAGE CO 80111 |
Abhinav Jain | director | C/O AYTU BIOPHARMA, INC., 373 INVERNESS PARKWAY, SUITE 206, ENGLEWOOD CO 80112 |
Wilmot B. Harkey | 10 percent owner | C/O NANTAHALA CAPITAL MANAGEMENT, LLC, 130 MAIN ST. 2ND FLOOR, NEW CANAAN CT 06840 |
Daniel Mack | 10 percent owner | C/O NANTAHALA CAPITAL MANAGEMENT, LLC, 130 MAIN ST. 2ND FLOOR, NEW CANAAN CT 06840 |
Nantahala Capital Management, Llc | 10 percent owner | 130 MAIN ST., 2ND FLOOR, NEW CANAAN CT 06840 |
Greg Pyszczymuka | officer: Chief Commerical Officer | C/O AYTU BIOPHARMA, INC., 373 INVERNESS PARKWAY, SUITE 206, ENGLEWOOD CO 80112 |
Richard I Eisenstadt | officer: Chief Financial Officer | 4819 EMPEROR BOULEVARD, SUITE 400, DURHAM NC 27703 |
Gerald W. Mclaughlin | director | 227 WASHINGTON STREET, SUITE 200, CONSHOHOCKEN PA 19428 |
Beth Hecht | director | C/O NEOS THERAPEUTICS, INC., 2940 N. HIGHWAY 360, GRAND PRAIRIE TX 75050 |
From GuruFocus
By ACCESSWIRE ACCESSWIRE • 11-17-2022
By ACCESSWIRE ACCESSWIRE • 02-21-2023
By ACCESSWIRE ACCESSWIRE • 01-06-2023
By ACCESSWIRE • 11-30-2023
By ACCESSWIRE • 09-22-2023
By ACCESSWIRE ACCESSWIRE • 06-13-2023
By ACCESSWIRE ACCESSWIRE • 01-25-2023
By ACCESSWIRE ACCESSWIRE • 06-14-2023
By ACCESSWIRE • 07-31-2023
By ACCESSWIRE ACCESSWIRE • 05-01-2023